Karachi: Liven Pharma Limited has announced a significant development in its business strategy with the signing of a contract manufacturing agreement with Skywin. This new collaboration, disclosed on December 10, 2025, marks a pivotal step for the pharmaceutical company as it expands its product line to include hormonal medicines and penicillin products.

The arrangement is expected to bolster Liven Pharma's market position, providing substantial benefits to its investors and shareholders. The company's management expressed optimism that this "bold and aggressive move" will drive dynamic growth.

According to information available from the Pakistan Stock Exchange (PSX), this agreement is in line with the compliance requirements of Clause 5.6.1(a) of the PSX Regulation and Section 96 of the Securities Act, 2015.

This strategic partnership is a testament to Liven Pharma's commitment to expanding its market reach and enhancing its product offerings in a competitive pharmaceutical landscape. The stakeholders have been advised to inform the TRE Certificate Holder of the Exchange about this development.